British researchers have identified a series of new drug compounds that could treat schistosomiasis, the London School of Hygiene & Tropical Medicine (LSHTM) announced on Wednesday.

LSHTM researchers and the nonprofit drug discovery company Salvensis screened more than 300,000 compounds—donated by the Medicines for Malaria Venture—to discover their ability to kill the three main species of parasitic worms.

In mouse models, the compounds were highly effective against both…

Japan’s Global Health Innovative Technology Fund announced $21 million in product development investments on Wednesday.

More than two-thirds of the awards will help advance six ongoing projects, while the rest fund four new investments: a leishmaniasis drug from Takeda and the Drugs for Neglected Diseases initiative; a malaria therapy from Eisai, the Medicines for Malaria Venture and the University of Dundee; a tuberculosis drug from Daiichi Sankyo RD Novare and the TB Alliance; and a…

Zydus Cadila announced last week that its ZY19489 (MMV253) malaria radical cure, co-developed with the Medicines for Malaria Venture, has succeeded in Phase 1.

The Ahmedabad-based company said healthy volunteers in Australia safely received escalating doses of 25 to 1,500 mg of the oral antimalarial compound. An additional P. falciparum malaria human challenge trial showed no serious or severe drug-related adverse events.

The results demonstrate that ZY19489 has the potential to…

Japan’s nonprofit Global Health Innovative Technology Fund (GHIT Fund) announced $2.2 million in drug development investments on Tuesday.

Three of the four awards support new projects for Chagas disease and malaria. The remaining award goes toward an ongoing drug discovery project between Takeda and Geneva-based Medicines for Malaria Venture.

GHIT Fund’s portfolio now includes 53 ongoing projects with $217 million invested so far, according to the press release.


An approved pediatric formulation of tafenoquine drew nearer last week after GSK and Medicines for Malaria Venture released new data showing that their single-dose radical cure for P. vivax malaria is safe and effective in children and adolescents ages 6 months to 15 years.

The Tafenoquine Exposure Assessment in Children (TEACH) study evaluated dosages of the oral 8-aminoquinoline drug based on weight, finding safety “consistent with previous clinical studies,” with 95% of subjects…


Geneva-based Medicines for Malaria Venture (MMV) yesterday launched Malaria Libre, an open-source antimalarial drug discovery program. Participating researchers will be able to access detailed information about compounds and upload their assay and other investigational results to a central MMV-moderated data repository.

MMV named India’s CSIR-Central Drug Research Institute, Jawaharlal Nehru University and TCG Lifesciences as early participants in the collaborative platform.

The state of the hunt: 

Moderna expects to begin Phase 3 trials of its mRNA-1273 vaccine candidate next month. J&J moved up the targeted launch of Phase 1/2a trials of its Covid-19 vaccine candidate from September to July. Sinovac teamed up with Instituto Butantan, which will sponsor Brazilian Phase 3 trials of the Chinese company’s inactivated vaccine candidate.



Existing candidates:
Moderna announced plans yesterday to commence Phase…

Announcing a $49 million, five-year grant, the European & Developing Countries Clinical Trials Partnership (EDCTP)—along with Medicines for Malaria Venture (MMV), Novartis and other partners—pledged to support the PAMAfrica research consortium in developing new malaria treatments.

The funds will back clinical trials in three areas: testing new combinations of compounds to treat drug-resistant uncomplicated malaria; evaluating Novartis’ cipargamin (KAE609) for severe malaria; and…

GSK and the nonprofit Medicines for Malaria Venture (MMV) announced Brazil last week as the first malaria-endemic country to approve their oral antimalarial tafenoquine for the radical cure of P. vivax malaria in patients 16 years of age and older.

GSK and MMV have been working together since 2008 to develop tafenoquine as a single-dose alternative to the existing standard of care, primaquine, which patients must take for either seven or 14 days.


Korea’s Research Investment for Global Health Technology (RIGHT) Fund announced its first four recipients of $5.8 million in grants last week at its 2019 investment forum.

EuBiologics (with Seoul’s International Vaccine Institute, Massachusetts General Hospital and Harvard Medical School) won support for its preclinical cholera conjugate vaccine.

SK Biotek (with the Medicines for Malaria Venture) will get funding for continuous process development and scale-up of new malaria…